Business Wire

Tap to Ride! Monterey-Salinas Transit Becomes 1st in California to Offer Riders the Ability to Tap to Pay with Visa

11.5.2021 14:00:00 EEST | Business Wire | Press release

Share

Today, in collaboration with Visa, Caltrans, Cybersource, Littlepay, and SC Soft, Monterey-Salinas Transit (MST) became the first transit agency in California to offer bus riders a contactless payment option. As cities begin to reopen, public transportation will play a critical role in recovery, and contactless payments can help provide a safe and easy experience for riders and transit operators seeking limited physical touchpoints and interactions. MST riders can now simply tap their contactless credit, debit, prepaid card or payment-enabled device on readers in MST buses for an easy and secure way to travel, without needing to purchase or load a separate transit card or handle cash while boarding.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005504/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Visa research shows that enabling tap to pay on transit systems like these can be good for economic recovery, bringing more than a 15% lift in transactions from merchants in surrounding neighborhoods1. MST is the fifth transit agency in the U.S. to accept tap to pay for fares, following Chicago, Miami, New York and Portland, OR. MST is also the first public transit system in the country that is located outside of a large urban area to introduce tap to pay fares – demonstrating contactless payments as a good fit for any size agency looking to enhance the customer experience.

“Visa recognizes the importance of expanding eligibility and access to fare payment options that meet the needs of a diverse set of transit riders,” said Brian Cole, SVP and head of North America product, Visa. “This effort with MST and Caltrans illustrates how open, contactless payments can support innovative and equitable fare policies to benefit riders and transit operators across the state.”

MST riders who tap will benefit from “fare capping” ensuring riders won’t pay more than $10.00 per day—as long as they pay with the same card or mobile wallet throughout the day. The tap to pay option on MST’s entire bus fleet is the first contactless payment demonstration of the California Integrated Travel Project (Cal-ITP), a Caltrans-led initiative to make travel simpler and more cost-effective for the 40 million California residents, served by 300-plus transit agencies, who collectively take approximately 1.3 billion2 passenger trips annually.

“We are committed to serving all of our riders and delivering new methods of ease and convenience,” said Carl Sedoryk, general manager and CEO, Monterey-Salinas Transit. “The availability of a contactless fare payment system means increased flexibility, and we are thrilled to be collaborating with Visa and Caltrans to bring the enhanced convenience and safety benefits of tap to pay to our community.”

Bringing the MST Demonstration to Life

Cybersource, a Visa solution, Littlepay, a transit-focused payments platform, and SC Soft, a transit ticketing and Automated Fare Collection specialist, have been critical in bringing the MST demonstration to life. Cybersource’s platform is powering the fast-to-market deployment of contactless solutions in the mass transit space, providing a full suite of payment and fraud management tools and an extensive network of partners and acquirers. Cybersource offers brand agnostic transit compliant processing solutions and enables easier implementation of digital payments for operators, while helping protect against fraud. Littlepay provides mass transit transaction processing, including the ability to cap fares and guarantee the best-value fare for frequent riders. SC Soft is a system integrator specializing in ticketing & Automated Fare Collection solutions for transit agencies around the world.

“Cybersource looks forward to supporting Cal-ITP partners to improve transit access within communities throughout the state,” said Fernando Souza, Vice President, Cybersource. “There is a great sense of urgency among transit operators to adopt these solutions and we are committed to powering secure, seamless contactless solutions in a world where no contact, touchless experiences are here to stay.”

“Removing barriers to transit ridership underscores what Cal-ITP is all about, and the launch of this contactless payment demonstration represents a significant step toward a simpler and more equitable public transit system throughout California,” said Caltrans Director Toks Omishakin.

Adoption of contactless payments continues to grow in the U.S. as more consumers realize they can pay for the things they need with a simple and secure tap. In the US, one in 10 face to face Visa transactions are now done with a tap, more than a 2x increase since the beginning of the pandemic, showcasing increased consumer preference for fast, touch-free payment experiences.

About Visa Inc.

Visa Inc. (NYSE: V) is the world’s leader in digital payments. Our mission is to connect the world through the most innovative, reliable, and secure payment network - enabling individuals, businesses and economies to thrive. Our advanced global processing network, VisaNet, provides secure and reliable payments around the world and is capable of handling more than 65,000 transaction messages a second. The company’s relentless focus on innovation is a catalyst for the rapid growth of connected commerce on any device, and a driving force behind the dream of a cashless future for everyone, everywhere. As the world moves from analog to digital, Visa is applying our brand, products, people, network and scale to reshape the future of commerce. For more information, visit About Visa, Visa’s Blog and @VisaNews.

__________

1 Visa Q2 FY21 Earnings Transcript
2 Caltrans, FY2018-2019

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Visa
Tierney Deggelman
650 418 0352
tdeggelm@visa.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye